Please use this identifier to cite or link to this item:
Title: Targeted therapy at the end of life for patients with lung cancer
Authors: Wong, A.S.
Teo, C.
Lim, S.-W. 
Wong, E.
Soo, R.A. 
Chan, N.
Issue Date: 1-Aug-2010
Citation: Wong, A.S., Teo, C., Lim, S.-W., Wong, E., Soo, R.A., Chan, N. (2010-08-01). Targeted therapy at the end of life for patients with lung cancer. Journal of Palliative Medicine 13 (8) : 945-948. ScholarBank@NUS Repository.
Abstract: The use of chemotherapy at the end of life is increasing. We characterized the use of targeted therapies in relation to the end of life in non-small cell lung cancer (NSCLC) patients who died in our institution. The frequency of systemic anticancer therapy usage at the end of life was consistent with that reported in other recent studies. The use of targeted therapies, especially epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), was strikingly more common than that of conventional chemotherapy. Targeted therapy was frequently initiated within the last 3 months of life. Targeted agents were also used in sequence, in combination, and in investigational protocols. We conclude that targeted agents, in particular EGFR TKIs, are now the drugs of choice in the systemic treatment of NSCLC at the end of life. Copyright 2010, Mary Ann Liebert, Inc.
Source Title: Journal of Palliative Medicine
ISSN: 10966218
DOI: 10.1089/jpm.2010.0084
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.